Title: Phase 1/2 study of FOG-001, a first-in-class direct β-catenin:TCF inhibitor, in patients with colorectal cancer, hepatocellular carcinoma, and other locally advanced or metastatic solid tumors.
Authors: Papadopoulos, Kyriakos P.; Cecchini, Michael; Khushman, Moh'd M.; Pelster, Meredith; Rodon Ahnert, Jordi; Kummar, Shivaani; Yaeger, Rona; Sharma, Sunil; Wells, Amber L.; Garofalo, Amanda; Akella, Lalith V; Yu, Ziyang; Iyer, Varsha; Nguyen, Marie Huong; Orford, Keith W.; Klempner, Samuel J.
Publication: Journal of Clinical Oncology, 2025, Vol 43, pTPS322
ISSN: 0732-183X
Publication type: Academic Journal
DOI: 10.1200/JCO.2025.43.4_suppl.TPS322

Phase 1/2 study of FOG-001, a first-in-class direct β-catenin:TCF inhibitor, in patients with colorectal cancer, hepatocellular carcinoma, and other locally advanced or metastatic solid tumors.

Papadopoulos, Kyriakos P.; Cecchini, Michael; Khushman, Moh'd M.; Pelster, Meredith; Rodon Ahnert, Jordi; Kummar, Shivaani; Yaeger, Rona; Sharma, Sunil; Wells, Amber L.; Garofalo, Amanda; Akella, Lalith V; Yu, Ziyang; Iyer, Varsha; Nguyen, Marie Huong; Orford, Keith W.; Klempner, Samuel J.